Immatics Reports a Confirmed Response Rate for IMA402 in Melanoma
Immatics reported a confirmed response rate for IMA402 in melanoma patients with high PRAME expression.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immatics reported a confirmed response rate for IMA402 in melanoma patients with high PRAME expression.